Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer-Reference-Cited by-同舟云学术

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Published:2001-09 Issue:9 Volume:12 Page:1247-1254
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

O’Shaughnessy J.A.,Blum J.,Moiseyenko V.,Jones S.E.,Miles D.,Bell D.,Rosso R.,Mauriac L.,Osterwalder B.,Burger H.-U.,Laws S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/12/9/1247/19479807/12-9-1247.pdf

Reference21 articles.

1. Breast cancer Epidemiology, risk factors, screening;Gairard;Rev Prat,1998

2. Cancer Statistics 1996 CA Cancer;Parker;J Clin,1996

3. Cancer incidence and mortality in the European Union Cancer registry data and estimates of national incidence for 1990;Black;Eur J Cancer,1997

4. Current management of metastatic breast cancer;Perez;Semin Oncol,1999

5. Patient preferences for oral vs intravenous palliative chemotherapy;Liu;J Clin Oncol,1997

Cited by 276 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16

2. Combination Chemotherapy Optimization with Discrete Dosing;INFORMS Journal on Computing;2023-11-09

3. Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study;Annals of Medicine & Surgery;2023-11-07

4. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial;European Journal of Cancer;2023-11

5. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition;Breast Cancer;2023-10-07